On the other hand, Corn et al. showed that carboplatin added to cabazitaxel (taxane agent) improved median progression-free survival and median overall survival in mCRPC patients with aggressive variants of PC including PTEN loss [135]. The gene discussed is PTEN; the disease is pachyonychia congenita.